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Introduction: Toxic shock syndromes (TSS) are severe shocks due to staphylococcal
or streptococcal infection that require specific treatments. The early recognition of these
shocks is crucial to improve their outcomes.
Objectives: The primary objective of this study was to compare characteristics and
outcomes of staphylococcal and streptococcal TSS in children, in order to identify
putative early clinical diagnostic criteria. Secondary objectives were to determine the
toxin gene profiles of associated isolated strains and the relevance of measuring Vβ T-cell
signatures to confirm the diagnosis.
Study design: We performed a multicenter retrospective evaluation of clinical data,
biological results, and treatment outcomes of children with a confirmed or probable case
of staphylococcal or streptococcal TSS. Children were consecutively included if they
were admitted to the pediatric intensive care units of Lyon (France), between January
2005 and July 2011.
Results: Among the 30 analyzed children, 15 presented staphylococcal TSS and
15 streptococcal TSS. The most frequent origin of staphylococcal and streptococcal
TSS was the lower respiratory tract (53%) and the genital tract (47%) respectively.
Non-menstrual TSS syndrome cases presented more frequently with neurological
alterations, and digestive signs were predominant in menstrual forms. Compared to
Staphylococcal TSS, Streptococcal TSS presented with higher organ dysfunction scores
(median Pediatric Index of Mortality 2 score 20.9 (4.1–100) vs. 1.7 (1.3–2.3), p = 0.001),
required respiratory support more frequently (80 vs. 33%, p = 0.02), were intubated for
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a longer time (3 days (0.75–5) vs. 1 day (0–1.5), p = 0.006) and had a non-significant
trend of higher, case-fatality rate (20 vs. 7%, p = 0.60). The lack of antitoxin therapy
was associated with higher case-fatality rate (50 vs. 4%, p = 0.04). The Vβ repertoire
measurements exhibited toxin dependent-alterations in accordance with the toxin gene
profiles of isolated strains in both types of toxic shock syndromes. Regarding toxin gene
profiles of isolated strains, 10/15 Staphylococcus aureus belonged to clonal complex
(CC) 30 and 6/12 Streptococcus pyogeneswere emm1 type suggesting clonal etiologies
for both staphylococcal and streptococcal TSS.
Conclusion: Despite the involvement of functionally similar toxins, staphylococcal and
streptococcal TSS differed by their clinical signs, origin of infection and prognosis. The
detection of Vβ profiles was useful to confirm the diagnosis of staphylococcal and
streptococcal TSS and for the identification of involved toxins.
Keywords: toxic shock syndrome, children, Staphylococcus aureus, Streptococcus pyogenes, Vβ T-cell signature,
antitoxin therapy
INTRODUCTION
Toxic Shock Syndrome (TSS) is a severe acute illness
characterized by high fever, hypotension, rash, multi-organ
system dysfunction, and desquamation during convalescence.
TSS is caused by toxin-producing strains of Staphylococcus
aureus or Streptococcus pyogenes and occurs in both adult and
pediatric patients (1–5). TSS remains a rare but severe disease,
with a mortality rate that varies from 4 to 27% for streptococcal
(Str) TSS (2–4) and from 0 to 22% for menstrual and non-
menstrual staphylococcal (Sta) TSS (1). Studies conducted in
pediatric intensive care units (PICU) reported a mortality rate
that can reach 25% for Str-TSS (2–6). The outcome of Sta-TSS
is more favorable in children than in adults (7, 8). TSSs have
a specific pathophysiology linked to superantigen exotoxins.
Superantigens (SAg), in contrast with conventional antigens,
do not need to be processed by antigen-presenting cells before
being presented to T cells. They instead directly stimulate T
cells by cross-linking major histocompatibility complex class
II molecules on the antigen-presenting cells with the variable
portion of the T-cell antigen receptor chain (Vβ TCR), thereby
inducing massive polyclonal cell proliferation (9, 10). Due to
their structural differences, each SAg links preferentially to one
or several Vβ repertoire, thus inducing targeted T cell expansion
and the massive pro-inflammatory response (11). A transient
depletion of targeted Vβ TCRs may be observed at the early
phase of TSS due to the concomitant lymphopenia, to the
mobilization/accumulation of T cells from peripheral blood to
lymph nodes or to the spleen, and/or from downregulation of
TCR molecules binding the toxin targeted Vβ repertoire(s) soon
after T cell activation (12).
The diagnosis of TSS is based on the association of
standardized clinical signs defined by the Centers for Disease
Control (CDC), but some of them may be transient (i.e.,
hypotension), lacking (i.e., cutaneous rash) or of delayed
occurrence (i.e., desquamation), and diagnosis is often difficult
during the early stages of the diseases (13, 14). Distinction
from septic shock, Kawasaki disease with shock, drug reaction
with eosinophilia and systemic symptoms (DRESS) syndrome
is sometimes difficult (15). Nevertheless, treatments of these
differential diagnoses differ significantly and early recognition
of these diseases is a key point for the prognosis. Because SAgs
are active at very low concentrations (<1 pg/mL) that are barely
detectable in vivo, the identification of ex vivo specific Vβ TCR
alterations could help to diagnose or to confirm TSS (16–26).
Early diagnosis of TSS is required because specific TSS
treatments with antitoxin effects must be added (1, 27) to
adapted antimicrobial chemotherapy: clindamycin, rifampicin
or linezolid to reduce exotoxin synthesis (2, 9, 28, 29), and
intravenous immunoglobulin (IVIG) therapy to neutralize the
SAg, especially in severe TSS (1–4, 7, 8, 30–36). Because of
severity of the disease, the clinical characteristics of Sta- and
Str-TSS have been primarily described in adult patients.
The objectives of this pediatric study were to compare
the characteristics and the outcome of staphylococcal and
streptococcal TSS in children to identify putative early clinical
diagnostic criteria; to identify factors associated with case-fatality;
to study the toxin gene profiles of associated isolated strains;
and to assess the relevance of measuring Vβ T-cell signatures to
confirm the diagnosis.
MATERIALS AND METHODS
Patient Selection
Selection of Eligible TSS Cases
The Sta- and Str-TSS cases were retrospectively selected by
searching for the keywords “toxic” or “toxin-associated shock
syndrome” in the hospital information system, as well as in the
medical records and databases of the two PICUs of the Hospices
Civils de Lyon, France (Debrousse Hospital and Edouard Herriot
Hospital from 2005 to 2008), then the PICU of the “Hôpital
Femme Mère Enfant” from 2008 to 2011 grouping those two
units when they closed. A supplemental research was performed
from the database of the French Staphylococcal and Streptococcal
National Reference Centers (NRC) which collects prospectively
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strains involved in staphylococcal and streptococcal diseases, and
notably toxin associated diseases. Appointed by Santé Publique
France, an agency of the FrenchMinistry of health, NRCmissions
include (i) strain expertises (identification, resistance, virulence,
and typing), (ii) epidemiological surveillance of infections (i.e.,
increase of incidence, new virulent factor, etc.), and (iii) advice to
public authorities, health agencies, and health professionals.
Included Cases
All records of the cases identified were reviewed by two authors
(CJ, EJ) to check if they met the CDC criteria for confirmed
and probable TSS cases (13, 14). Sta-TSS patients with all CDC
criteria but desquamation were included in the probable Sta-TSS
group, as this sign mainly occurred lately in the course of the
disease and was therefore lacking in the PICU’s medical record.
Collected Data
Clinical and biological data, including pediatric index of
mortality (PIM 2), pediatric logistic organ dysfunction (PELOD)
scores and 30 days outcomes (length of PICU stay and mortality)
were collected anonymously (37, 38).
Ethics Statements
According to the French policies, our study was defined as a
non-interventional study as it met the following two criteria:
(i) parents of children included in the database have received
information about the study and (ii) an non-formalized right of
opposition was collected in the clinical records. Regarding this
lack of written informed consent, patient records were collected
anonymously and de-identified prior to analysis. Thus, this study
was approved by an institutional ethics review board (“Comité de
Protection des personnes Sud Est IV, DC-2008-176”).
Immunological Data
Blood samples were collected in EDTA tubes from 1 to 4 days
(D) after PICU admission to measure VβCD3+T cell alterations.
Due to the initial lymphopenia, the mobilization/accumulation
of T cells from peripheral blood to lymph nodes or to the spleen,
and/or from downregulation of TCRmolecules binding the toxin
targeted Vβ repertoire(s) soon after T cell activation, a second
measurement was performed between D+3 and D+8 of PICU
admission in case of massive decrease of one or association of
Vβ repertoires known to be targetet by SAg. These measurements
could only be performed 5 days a week (Monday–Friday) which
explains that the first determination could range from D+1
to D+4 and the second from D+3 to D+8. The physicians
responsible for case coding as well as those responsible for the
clinical PICU’s databases were not aware of the results of these
immunological investigations.
The peripheral blood mononuclear cells were stained with
CD3 and 24 TCR Vβ element antibodies (IO Test Beta Mark R©
kit, Beckman Coulter, Marseille, France) and analyzed with
FACScan R© flow cytometer (BD, Pont de Claix, France), as
previously described (25). Based on our previous data that
showed an association between TCR Vβ expansions and involved
staphylococcal toxin, we limited the measure of Vβ CD3+T cell
alterations to these 24 out of 65 known human Vβ elements.
Microbiological Data
Different anatomical sites were sampled and sent for
microbiological analysis (culture and isolation of S. aureus or S.
pyogenes) in order to identify etiology and source of infection.
Strains were identified by biochemical tests, such as clumping
factor, the coagulase test or Lancefield group agglutination
(bioMérieux, Marcy l’Etoile, France), and with Phoenix R© strips
(BD, Pont de Claix, France) or mass spectrometry (VITEKMS R©,
BioMérieux, France). Antibiotic susceptibilities were determined
using a Phoenix 100 R© instrument (BD) or by the disc diffusion
method (SIRSCAN R© I2A, Peyrols, France) following CA-SFM
guidelines.
Toxin Gene Profiles of S. aureus Strains Determined
by the French NRC of Staphylococci
The toxin gene profiles of S. aureus isolates were characterized
for all patients. Staphylococcal DNA was extracted (Qiagen,
Courtaboeuf, France), and the toxin gene profile was determined
using Identibac S. aureusGenotyping R© DNAmicroarrays (Alere,
Jouy en Josas, France), as previously described (39). This
Identibac S. aureus Genotyping R© DNA microarray screened
genes for strains identification, virulence factors, resistance and
allow for the assignment to a probable clonal complex (CC) (39).
Toxin Gene Profiles and M Protein Typing of S.
pyogenes Strains Determined by the French NRC of
Streptococci
The toxin gene profiles of S. pyogenes isolates were characterized
for 12/15 patients (three strains were not transmitted to the
French NRC for streptococci). As previously described, S.
pyogenes strains were analyzed to determine their gene profiles
of superantigenic toxins and M protein types (emm) (8) by PCR.
Statistical Analysis
Data were analyzed with SPSS for Windows version 17.0
(SPSS Inc., Chicago, Illinois, USA). Qualitative variables were
compared with a Chi-Square test supplemented by Fisher’s exact
test for low effective groups (n < 5). Quantitative variables are
reported as the means and standard deviation or as medians and
quartiles 1 and 3 for the variables that had distributions that were
not normal. The Kolmogorov-Smirnov test was used to study
the normality of the distribution of the continuous variables.
The quantitative variables were compared with Student’s t-test or
with a non-parametricWilcoxon test depending on the normality
of their distribution. P-values below 0.05 were considered to
indicate statistical significance.
RESULTS
Characteristics of the Study Population
Among the 34 patients identified from the cross-analysis of the
databases, 30 (11 boys and 19 girls) were finally included in
the study. Among them, 15 Str-TSS cases (11 confirmed and 4
probable cases according to the CDC criteria) and 15 Sta-TSS
cases, 6 of which were menstrual Sta-TSS and 9 non-menstrual
Sta-TSS (4 confirmed cases and 8 probable cases according to the
CDC criteria) were included. The four excluded patients were 1
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Stevens-Johnson syndrome, 1 Kawasaki syndrome with shock, 1
severe Panton-Valentine staphylococcal infection and 1 patient
hospitalized in an intermediate care unit. The median age was 5.2
years (interquartile range: 1.4–12.8, Table 1). S. pyogenes were
isolated in all the patients.
Comparison Between Patients With
Staphylococcal and Streptococcal Toxic
Shock Syndrome
Children with Str-TSS were significantly younger than children
with Sta-TSS [1.7 years (0.7-5.4) vs. 12.8 years (5–15.7),
p = 0.001]. At day 1, compared to Sta-TSS patients, Str-TSS
patients needed ventilation support more often and had longer
ventilation duration [3 days (0.75–5) vs. 1 day (0–1.5), p= 0.006];
had higher leukocyte counts (22.3 vs. 14.6 G/L, p = 0.049) and
significantly higher CRP levels (238.8+/– 103.8 vs. 164+/– 82.8
mg/l, p = 0.04, respectively) and presented with significantly
higher PIM 2 score (median 20.9 (4.1–100) vs. 1.7 (1.3–2.3), p
= 0.001) Other clinical variable were similar in the two groups.
The primary origin of the Str-TSS was the lower respiratory
tract (53% of Str-TSS cases) whereas menstrual and non-
menstrual Sta-TSS involved the vagina, and the skin or the upper
respiratory tract respectively (Table 2).
TABLE 1 | Clinical and biological characteristics of patients with staphylococcal or streptococcal toxic shock syndrome.
Missing data Sta-TSSa
(n = 15)
Str-TSSb
(n = 15)
p
Demographical characteristics Male (%c) 0 4 (27%) 7 (47%) 0.45d
Age (years) median (Q1-Q3e) 0 12.8 (5–15.7) 1.7 (0.7–5.4) 0.001f,*
Hemodynamic characteristics Hypotension (%) 0 15 (100%) 15 (100%) 1g
Need of amine support (%) 0 10 (67%) 12 (80%) 0.68g
Duration of treatment with amines (days) median (Q1-Q3) 0 1 (0–1.8) 2 (0.8–3) 0.17f
Pulmonary signs FiOh2 > 50% (%) 1 5/14 (36%) 13/15 (87%) 0.01
g,*
Requirement of mechanical ventilation (%) 0 5 (33%) 12 (80%) 0.02g,*
Duration of intubation median (days) (Q1-Q3) 0 1 (0–1.5) 3 (0.75–5) 0.006f,*
ARDSi (%) 2 1/14 (7%) 5/14 (36%) 0.16d
Organ dysfunctions Creatinine, maximum value (µmol/L) mean (SDj) 0 122.1 (115.8) 68.3 (49.6) 0.11k
Liver alterationsl (%) 2 10/14 (71%) 8/14 (57%) 0.69g
Number of organ dysfunctionl median (Q1-Q3) 0 3 (2–4) 4 (3–5) 0.13f
Cutaneous signs Rash (%) 0 15 (100%) 11 (73%) 0.10g
Desquamation (%) 6 5/13 (39%) 3/11 (27%) 0.68d
Digestive signs (%) 0 11 (73%) 7 (47%) 0.26g
Inflammatory parameters Fever ≥ 38.9◦C (%) 0 15 (100%) 15 (100%) 1g
Leukocytes, minimum value (G/L)mean (SD) 0 8.6 (3.7) 8.5 (6.3) 0.95k
Leukocytes, maximum value (G/L) mean (SD) 0 14.6 (6.2) 22.3 (13) 0.049k,*
Lymphocytes, minimum value (G/L) median (Q1-Q3) 2 0.2 (0.1–1.2) 0.6 (0.5–0.9) 0.056f
C-Reactive Protein (mg/L) mean (SD) 2 164 (82.8) 238.8 (103.8) 0.044k,*
Hemostasis parameters Platelets, minimum value (G/L) mean (SD) 0 124.8 (52.5) 140.2 (100.6) 0.61k
Disseminated Intravascular Coagulation 1 8/15 (53%) 8/14 (57%) 1g
Severity scores and outcome PIM2m score median (Q1-Q3) 3 1.7 (1.3-2.3) 20.9 (4.1-100) 0.001f,*
PELODn J1 score median (Q1-Q3) 1 11 (11-21) 16.5 (11.8–25) 0.15f
Length of stay in ICU
◦
(days) median (Q1-Q3) 0 3 (2-4) 6 (3–9) 0.02f,*
30 day death 0 1 (7%) 3 (20%) 0.60 d
aSta-TSS, Staphylococcal Toxic Shock Syndrome.
bStr-TSS, Streptococcal Toxic Shock Syndrome.
c% percent of total population.
dStatistical analysis performed with Fisher exact test.
eQ1-Q3, Interquartile range.
fStatistical analysis performed with Wilcoxon test.
gStatistical analysis performed with Chi-square test.
hFiO2, Fraction of inspired Oxygen.
iARDS, Acute Respiratory Distress Syndrome.
jSD, standard deviation.
kStatistical analysis performed with Student t-test.
lLiver alterations and organ dysfunctions were defined in CDC criteria for case definition of toxic shock syndrome (13, 14).
mPIM2 Pediatric Index of Mortality 2 score.
nPELOD Pediatric Logistic Organs Dysfunctions score.
◦
ICU, Intensive Care Unit.
*Statistically significant data with the corresponding statistical test.
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TABLE 2 | Infectious source of patients with staphylococcal and streptococcal
toxic shock syndrome.
Etiological infectious sites Staphylococcal Streptococcal
TSSa TSS pb
(n = 15) (n = 15)
Bacteremia 1 (7%) 6 (40%) 0.08
Pleura or lung 1 (7%) 8 (53%) 0.01*
Postoperative TSS 0 (0%) 2 (13%) 0.48
Skin and soft tissues 4 (27%) 3 (20%) 1
Upper respiratory tract 3 (20%) 3 (20%) 1
Vagina 7 (47%) 0 (0%) 0.006*
Varicella superinfection 2 (13%) 3 (20%) 1
Indefinite 0 (0%) 1 (7%) 1
aTSS, Toxic Shock Syndrome; bStatistical analysis performed with Chi-square test.
*Statistically significant data (p<0.05) with the corresponding statistical test.
There was no difference between groups regarding IVIG use
(53% for Str-TSS and 47% for Sta-TSS, p=1) or the use of anti-
infectious agents with antitoxin effects (clindamycin, linezolid,
rifampicin; 93% for Str-TSS and 87% for Sta-TSS, p= 1).
Comparison Between Menstrual and
Non-menstrual Staphylococcal Toxic
Shock Syndrome
The most striking difference between menstrual and non-
menstrual Sta-TSS was the constant presence of gastrointestinal
signs (i.e., abdominal pain and emesis) in menstrual Sta-TSS (100
vs. 50%, p = 0.08) There was also a non-significant trend toward
a higher frequency of neurological symptoms (i.e., confusion,
impaired consciousness) in non-menstrual Sta-TSS (50 vs. 14%,
p= 0.28).
Factors Associated With Case-Fatality:
Our retrospective study reported 4/30 deaths (13%) (Table 3).
The non-survivors significantly presented with more organ
dysfunctions, with a higher occurrence of acute respiratory
distress syndrome and with a higher PELOD score measured
at D+1. The case-fatality rate was not significantly different
between the Staphylococcal and Streptococcal TSS groups (7 vs.
20% p = 0.60). All the children received adapted antimicrobial
therapies for S. aureus or S. pyogenes, and 27/30 received an
antitoxin therapy (clindamycin or clindamycin + IVIG) with a
significant association with survival (Table 3). Among the 4 non-
survivors, three died rapidly (one during the transport to PICU,
one 4 h after arrival, one had presented a cardiac arrest just prior
to PICU admission), and only one of them received an antitoxin
antibiotic.
Microbiological Features
S. aureus strains belonged to the accessory gene regulator
(Agr)1 (2/15), Agr2 (2/15) or Agr3 (11/15) genetic backgrounds.
According to DNA microarrays assignments, 10/15 belongs to
clonal complex (CC) 30, 1/15 to CC5, 1/ 15 to CC45, 1/15
to CC22, and the sole MRSA strain is CC5 and belongs to
Geraldine clone. All menstrual Sta-TSS strains contained the
TSS toxin gene (tst) that encodes TSS toxin −1 (TSST-1),
the staphylococcal enterotoxin A gene (sea) gene that encodes
staphylococcal enterotoxin (SE) A (4/7), the enterotoxin gene
clusters (egc) that encode SEG, SEI, staphylococcal enterotoxin
like (SEl) M, SElN and SElO (5/7). The non-menstrual Sta-
TSS isolates were characterized by the presence of the tst gene
encoding TSST-1 (6/8), seb (1/8), or sec (1/8) in association with
other toxin genes; the most frequently found toxin genes were sea
(4/8) and egc (7/8). Only one strain involved in non-menstrual
Sta-TSS was resistant to methicillin.
S. pyogenes strains were primarily types emm1 (6/12) or
emm12 (2/12). Toxin gene analysis showed the following 4
different profiles: contained the streptococcal pyrogenic exotoxin
A (speA) and speC genes encoding streptococcal pyrogenic
exotoxin (SPE) A and SPEC, respectively (2/12), contained only
the speA gene (4/12), contained only speC (5/12) or contained
neither speA nor speC but did encode speB (1/12). The gene speB
was present in all S. pyogenes strains included in our study.
Immunological Features: Superantigenic
Toxins and Vβ T-Cell Signatures
The Vβ repertoire profile of CD3+ T cells (Vβ profile) was
determined at D1-4 after PICU admission in a subset of 18/30
patients that included 12 Sta-TSS and 6 Str-TSS cases (Tables 4,
5). Targeted by TSST-1, a significant Vβ2 alteration was observed
in all confirmed and probable TSS-Sta cases. Whereas, a Vβ2
increase was measured for 8/12 (67%) Sta-TSS patients, it was
delayed for 4 Sta-TSS cases with initially a large decrease of
Vβ2 repertoire followed by a large expansion at the second
measurement performed between D3 and D5. A correlation
between the number of organ dysfunctions and the level of
Vβ2 expression on CD3+ T cells between days 3 and 5 post-
Sta-TSS onset was found (Figure 1). Regarding 6 Str-TSS cases,
expansions of some or all Vβ repertoires targeted by SPEA or
SPEC were also measured in all confirmed and probable Str-TSS
cases at the first determination (Table 5).
DISCUSSION
This retrospective analysis of 30 consecutive cases of
Staphylococcal and Streptococcal TSS, admitted to the PICUs
of the city of Lyon in France, showed differences between
groups regarding clinical presentation, origin of infection, and
outcome. However, pathophysiological mechanisms involving
superantigenic toxins were consistent between groups. We
showed that the detection of Vβ profiles could confirm the
diagnosis of Staphylococcal and Streptococcal TSS cases, signing
a toxin involvement, correlated to the toxin gene profile of the
isolated strains.
Clinical Findings
Str-TSS patients were younger than Sta-TSS patients, with 47%
of patients younger than 2 years, in agreement with previous
studies (2, 4–6). Regarding their clinical signs, TSS associated
with para-pneumonic empyema was highly suggestive of a
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TABLE 3 | Comparison of clinical characteristics and effects of antitoxin therapies on live vs. dead TSS cases.
Dead (n = 4) Survivor (n = 26) P
Etiology of toxic shock syndrome p = 0.5977
- Sta-TSSa (%)b 1 (7%) 14 (93%)
- Str-TSSc (%) 3 (20%) 12 (80%)
Number of organ dysfunctions (SDd) 5 (0, 8) 4 (1, 3) p = 0.04*
ARDSe (%) 4/4 (100%) 4/26 (15%) p = 0.04*
PELODf score at D+1 (SD) 28 (13, 7) 12 (7, 1) p = 0.04*
Antitoxin therapies (overall) p = 0.04*
- No treatment (%) 2 (67%) 1 (33%)
- At least one antitoxin therapies (clindamycin; clindamycin + IVIGg ) (%) 2 (7%) 25 (93%)
Antitoxin therapy: clindamycin only p = 0.0813
- No treatment (%) 2 (67%) 1 (33%)
- Clindamycin only (%) 1 (8%) 11 (92%)
Antitoxin therapy: clindamycin + IVIG p = 0.5977
- No treatment (%) 3 (20%) 12 (80%)
- Clindamycin + IVIG (%) 1 (7%) 14 (93%)
Antitoxin therapy: clindamycin + IVIG p = 1.0000
- Clindamycin only (%) 1 (8%) 11 (92%)
- Clindamycin + IVIG (%) 1 (7%) 14 (93%)
aSta-TSS, Staphylococcal Toxic Shock Syndrome.
b%, percent of total population.
cStr-TSS, Streptococcal Toxic Shock Syndrome.
dSD, standard deviation.
eARDS, Acute Respiratory Distress Syndrome.
fPELOD, Pediatric Logistic Organs Dysfunctions score.
g IVIG, Intravenous Immunoglobulin.
*Statistically significant data with the corresponding statistical test.
streptococcal origin. Conversely, menstrual Sta-TSS should be
suspected in a young adolescent girl with hypotension, rash,
gastrointestinal symptoms and fever, whereas non-menstrual Sta-
TSS may include a very heterogeneous group of patients in terms
of age, gender and comorbidities.
Str-TSS cases had a more severe prognosis than the Sta-TSS
cases, including longer PICU stay, higher PIM2 scores, higher
number of organ failure with more frequent acute respiratory
distress syndrome, and required mechanical ventilation more
often and for a longer time, in accordance to UK and Australian
studies (5, 6, 40). Although not significant, the case-fatality rate
for Str-TSS (20%) was higher than Sta-TSS (7%), that is consistent
with the meta-analysis of Chuang et al., who analyzed 27 and
30 studies focused on Sta- and Str-TSS, respectively. They found
a 5 to 10% case-fatality rate for Str-TSS, a 3% case-fatality rate
for menstrual Sta-TSS and a 5% rate for non-menstrual Sta-
TSS (7). Moreover, three later studies that included critically ill
children found a case-fatality rate between 20 and 30% for Str-
TSS (2, 4, 6); however, that remains below the case-fatality rate
(45%) estimated for adults by the French NRC between 2006 and
2010 (1). Recently, Chen et al. reported an absence of death in
a large cohort of 62 Staphylococcal and Streptococcal TSS cases
(5, 6).
Factors Associated With Case-Fatality
We found a significantly lower case-fatality rate in patients
treated with at least one antitoxin therapy (clindamycin or
FIGURE 1 | Correlation between organ dysfunctions and Vβ2 expression on
CD3+ T cells. Correlation between the number of organ dysfunctions and the
Vβ2 expression measured on CD3+ T cells between days 3 and 5 after the
onset of staphylococcal toxic shock syndrome. Pearson’s correlation (R2) was
used to measure co-linearity between the selected independent variables.
clindamycin + IVIG) (Table 3). This result was in line with
a recent study on TSS-Str demonstrating that clindamycin
treatment substantially reduced mortality rate (41, 42). This
effect may be enhanced by concurrent treatment with IVIG,
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contrasting with a previous study suggesting that IVIG had no
effect (3, 41). Causality of our results cannot be ascertained
because of the retrospective study design with no adjustment for
disease severity (i.e., the lack of antitoxin therapy could be due to
a misdiagnosis). This supports the need for a large randomized
prospective trial, especially to test IVIG.Moreover, this difference
in survival rates is likely to be due to the impossibility to receive
such urgent treatments in time, because of the very high severity
of the disease.
Microbiological and Immunological
Findings
In accordance with DeVries et al. study which included any
positive culture for S. aureus (including infection as well as
carriage strains) and obtained strain in 72% of the examined
cases, we systematically isolated S. aureus strains, suggesting
a selection bias in our population based on TSS criteria (43).
However, in agreement with other studies, bacteremia was rare
in Sta-TSS (<5%) and significantly more frequent in the Str-
TSS (40 to 60%) (7). Because characterization of the toxin gene
profile of isolates was not mandatory for the inclusion analysis,
only 90% were characterized: The 15 isolated S. aureus strains
belonged to 3 different agr groups, and 13/15 carried at least tst.
Eleven of the S. aureus strains were Agr3, and among them, 6
exhibited similar toxin gene profile associating tst, sea, egc and
seu, and belongs to clonal complex 30 (44). These results suggest
the presence of a dominant S. aureus clone involved in Sta-
TSS in France as recently described in United Kingdom. This
CC30 MSSA produces more TSST-1 and induces more T-cell
proliferation than CC30 MRSA (45). Similarly, Str-TSS were due
to a dominant clone of S. pyogenes characterized by an emm1 gene
encoding the M1 protein and speA, in agreement with previous
studies (8).
Specific treatments appear most effective when administered
early in the development of the disease; thus TSS should be
diagnosed as early as possible. However, TSS diagnosis based
on the CDC criteria is difficult (43) because some criteria occur
lately or rarely, resulting in under-diagnosis of TSS cases (11).
Moreover, differential diagnosis with septic shock or Kawasaki
syndrome with shock and DRESS syndrome is sometimes
challenging because of the association of shock, cutaneous rash
andmulti organ dysfunctions in these conditions. Parsonnet et al.
suggested that the integration of other laboratory criteria such as
the isolation of S. aureus, the production of TSST 1 (or another
superantigen) and the absence of antibodies against superantigen
produced by the host could increase the accuracy of TSS
diagnosis (46). Based on a biological test measuring functional
effects of SAgs on immune system, our study used Vβ profile
test to improve TSS diagnosis. As previously described (18),
Vβ2 alterations (initial decrease followed by large expansion)
correspond to the activation of T cells by TSST-1 and were
observed in each of the 12 Sta-TSS cases. Each of the eight
Sta-TSS cases, classified as probable according to the CDC
criteria and for which Vβ profile was studied, showed a Vβ 2
repertoire expansion similar to other confirmed Sta-TSS cases.
Similarly, Vβ expansions corresponded to partial or complete
profiles of streptococcal SAgs produced by the clinical isolates
were measured in 6/6 patients with Str-TSS. However, in two
cases of Str-TSS, the Vβ expansions were difficult to interpret
due to partial Vβ profiles when they were compared to the Vβ
specificity from the literature (16, 19, 21, 23, 24, 26). These
partial profiles may be due to residual neutralizing effects of
IVIG infusion before measurement of Vβ repertoire profiles.
These discrepancies may also be explained by differences in the
methods used to detect Vβ expansions (other sets of antibodies
or RT-PCR), the length of the incubation and the use of different
cut-off values used to define significant enhancement of Vβ
alterations. Ideally, we should determine the Vβ specificity of
streptococcal superantigens using a flow cytometric test that
has been used for S. aureus superantigens (10, 25). Although
there is no control group due to the retrospective collection
of cases, our study described, for the first time, the use of
Vβ profiles to characterize a large pediatric TSS population.
This biological test, which was positive in probable as well as
confirmed TSS, could identify the toxin involved in the TSS
and show alterations at the first measurement, which could help
diagnosing or confirming TSS cases. This test may allow for an
early (within the first 24–48 h) diagnosis of Sta-TSS, especially in
non-menstrual cases, showing a large decrease of Vβ2 associated
with severe lymphopenia. Later on (after 48 h), when expansion
would confirm the diagnosis whenever the doubt persists; for
example when no staphylococcus has been isolated yet.
In contrast, Ferry et al. found no discriminant Vβ signature
in septic shock (27), suggesting a high specificity of the Vβ
profile for TSS. At least, the Vβ profile might thus constitute
a new tool to improve the diagnosis of toxic shock and might
also improve the TSS diagnosis criteria of the CDC. However,
additional studies are required to evaluate its relevance in partial
or doubtful form of TSS cases according to CDC criteria.
Limitations
The retrospective nature of our study did not allow
interpreting reliably the impact of antitoxin therapy
on survival. The inability to perform Vβ profile for all
patients at a same time point may bias the analysis of the
performance of this biological diagnosis test. However,
these preliminary results are consistent with those found in
adults and require a validation by a prospective multicenter
study.
The low sample size did not allow for multifactorial analysis
that would have strengthened our findings.
CONCLUSION
Sta- and Str-TSS are induced by similar toxins produced
by strains with limited diversity which suggests a clonal
origin of French strains involved in TSS. However, they differ
in their clinical presentations (pulmonary involvement vs.
gastrointestinal signs), their source of infection (bacteremia vs.
vaginal localization), their severity and their prognosis. The
detection of Vβ profiles was helpful for the diagnosis of probable
TSS cases and for the identification of toxin involvement but
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future investigations are required to extensively identify the Vβ
profiles of streptococcal toxins. However, this test might be added
to the TSS diagnosis criteria in the future. Antitoxin therapies
(clindamycin and/or IVIG) were associated with a better survival.
However, a potential bias related to the discrepancy in the timing
of treatment delivery may limit the interpretation of these results.
The conduct of a large randomized controlled trial is mandatory
to assess IVIG and anti-toxin chemotherapy efficacy.
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